Company intelligence / Profile preview

Sama

Cambridge, Massachusetts, United Statessama.band ↗

Ownership: Private
Development stage: Preclinical

Overview

Their iMAGiNE™ platform has demonstrated the ability to differentiate major psychiatric disorders by predicting treatment response over 50% better than current state-of-the-art methods across multiple modalities (“transprognostic”). Award-winning predictive capabilities validated in international competitions.

Therapeutic areas: PsychiatryNeurology
Modalities: Software as medical device (SaMD)Antibody (in partnership programs)Digital biomarker platformArtificial intelligence-powered analytics
Industry: Digital Health Medical Devices

Partnerships

Quine Biologics

Beyond the preview

Go deeper on Sama.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sama.

Explore the full profile